Skip to main content

Advertisement

Table 3 Additional benefit claims based on types of sponsor

From: Phase IV non-inferiority trials and additional claims of benefit

   Additional benefit (row percentage)
   Not mentioned Convenient method of administration Better safety profile Better compliance Less costly Convenient method of administration and better safety profile Convenient method of administration, better safety profile, better resistance profile
Type of initiators Non-pharmaceutical industry (n = 12) 7 (59) 0 4 (33) 0 0 0 1 (8)
Pharmaceutical industry (n = 25) 11 (44) 1 (4) 8 (32) 1 (4) 1 (4) 3(12) 0
Not clear (n = 4) 1(25) 0 0 2 (50) 0 1 (25) 0
Conclusion of the trial Non-inferiority (n = 30) 15 (50) 1 (3) 8 (27) 3 (10) 0 2 (7) 1 (3)
Superiority (n = 2) 0 0 2(100) 0 0 0 0
Inferiority (n = 6) 2 (33) 0 1(17) 0 1(17) 2 (33) 0
  Other (n = 3) 2 (67) 0 1 (33) 0 0 0 0